ID   U-1906L
SY   U-1906 L; 1906L; U-1906 Late passage
DR   IARC_TP53; 18698
DR   Wikidata; Q54973532
RX   PubMed=7655829;
RX   PubMed=12820372;
RX   PubMed=21508355;
CC   Doubling time: 55.0 +- 17.36 hours (PubMed=7655829).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=12820372).
CC   Derived from metastatic site: Brain.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_D075 ! U-1906
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 23-09-21; Version: 6
RX   PubMed=7655829; DOI=10.1016/0169-5002(95)00444-6;
RA   Brodin O., Arnberg H., Bergh J., Nilsson S.;
RT   "Increased radioresistance of an in vitro transformed human small cell
RT   lung cancer cell line.";
RL   Lung Cancer 12:183-198(1995).
RX   PubMed=12820372;
RA   Bergqvist M., Brattstrom D., Gullbo J., Hesselius P., Brodin O.,
RA   Wagenius G.;
RT   "p53 status and its in vitro relationship to radiosensitivity and
RT   chemosensitivity in lung cancer.";
RL   Anticancer Res. 23:1207-1212(2003).
RX   PubMed=21508355;
RA   Hedman M., Bergqvist M., Brattstrom D., Brodin O.;
RT   "Fractionated irradiation of five human lung cancer cell lines and
RT   prediction of survival according to a radiobiology model.";
RL   Anticancer Res. 31:1125-1130(2011).